ALOX5 Polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma

Clinical and Experimental Allergy

Volumn 43, Issue 5, 2013, Pages 512-520

  Mougey, E ^a   Lang, J E ^a,b   Allayee, H ^c   Teague, W G ^d   Dozor, A J ^e   Wise, R A ^f   Lima, J J ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b NEMOURS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Lipoxygenase; ALOX5; Asthma; Asthma control; Children; Exhaled nitric oxide; FEV1; Genetic association; Leukotriene

Indexed keywords

ALOX5 PROTEIN; LEUKOTRIENE A4; NITRIC OXIDE; PEPTIDOLEUKOTRIENE; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; AFRICAN AMERICAN; ALLELE; ALLERGY; ARTICLE; ASTHMA; ATOPY; CHILD; CLINICAL EVALUATION; DISEASE CONTROL; DNA POLYMORPHISM; FAMILY HISTORY; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC MODEL; GENOTYPE; HOMOZYGOSITY; HUMAN; LOW BIRTH WEIGHT; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT INFLAMMATION; SCHOOL CHILD; SECONDARY ANALYSIS; SLEEP DISORDERED BREATHING; URINE LEVEL;

ADOLESCENT; ALLELES; ARACHIDONATE 5-LIPOXYGENASE; ASTHMA; BINDING SITES; CHILD; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKOTRIENE E4; LEUKOTRIENES; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RESPIRATORY FUNCTION TESTS; SP1 TRANSCRIPTION FACTOR;

EID: 84876707395     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12076     Document Type: Article

References (22)

1. Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980-2007. Pediatrics 2009; 123(Suppl 3):S131-45.
2. Akinbami LJ, Rhodes JC, Lara M. Racial and ethnic differences in asthma diagnosis among children who wheeze. Pediatrics 2005; 115:1254-60.
3. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987; 136:985-98.
4. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001; 119:1533-46.
5. Woods JW, Evans JF, Ethier D et al. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 1993; 178:1935-46.
6. In KH, Asano K, Beier D et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130-7.
7. Drazen JM, Yandava CN, Dube L et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168-70.
8. Lima JJ, Zhang S, Grant A et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173:379-85.
9. Telleria JJ, Blanco-Quiros A, Varillas D, Armentia A, Fernandez-Carvajal I. Jesus Alonso M, Diez I, ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 2008; 102:857-61.
10. Vikman S, Brena RM, Armstrong P, Hartiala J, Stephensen CB, Allayee H. Functional analysis of 5-lipoxygenase promoter repeat variants. Hum Mol Genet 2009; 18:4521-9.
11. Kim SH, Bae JS, Suh CH, Nahm DH, Holloway JW, Park HS. Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness. Allergy 2005; 60:760-5.
12. Rabinovitch N. Urinary leukotriene E4. Immunol Allergy Clin North Am 2007; 27:651-64; vii.
13. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-7.
14. Holbrook JT, Wise RA, Gold BD et al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA 2012; 307:373-81.
15. Standardization of Spirometry. Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152:1107-36.
16. Dwyer JH, Allayee H, Dwyer KM et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004; 350:29-37.
17. In KH, Silverman ES, Asano K et al. Mutations in the human 5-lipoxygenase gene. Clin Rev Allergy Immunol 1999; 17:59-69.
18. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171:912-30.
19. Dal Negro RW, Visconti M, Micheletto C, Tognella S, Guerriero M. Reference urinary LTE4 levels in normal individuals: a pilot study. Eur Ann Allergy Clin Immunol 2011; 43: 22-8.
20. De Caterina R, Zampolli A. From asthma to atherosclerosis-5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med 2004; 350:4-7.
21. Kalayci O, Birben E, Sackesen C et al. ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. Allergy 2006; 61:97-103.
22. Green SA, Malice MP, Tanaka W, Tozzi CA, Reiss TF. Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax 2004; 59:100-4.